-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
On March 22, Harmonicare announced that its anti-CTLA-4 antibody HBM4003, an open phase 1 study for patients with advanced melanoma and other solid tumors in China, has completed the first patient medication.
CTLA-4 is one of the main negative regulators of T cell response.
According to relevant information from Hebo Medicine, HBM4003 is a new generation of anti-CTLA-4 fully human monoclonal heavy chain antibody independently developed by the company and produced on the Harbour Mice® platform of Hebo Medicine.
In the preclinical mouse pharmacodynamic study, HBM4003 single agent showed significantly improved anti-tumor efficacy.
According to the press release, the completion of the first patient medication this time is an open phase 1 study of HBM4003 in combination with teriprizumab for patients with advanced melanoma and other solid tumors.
It is worth mentioning that the clinical trial application for the combination of HBM4003 and PD-1 antibody/chemotherapy for the treatment of patients with advanced non-small cell lung cancer and other solid tumors was approved in China one month ago.
Note: The original text has been deleted
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
